Loading
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Previous close
$53.89
−$1.50 · -2.71%
Pre-market
$53.99
+$0.10 · +0.19%
Sep 14, 8:00 AM ET
Regular session · ET · Market data may be delayed.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Day range
Current $53.89
52-week range
Current $53.89
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
87
Deep Value
Sentiment
73
Bullish
Risk
41
Elevated Risk
Momentum
74
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Day range
Current $53.89
52-week range
Current $53.89
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 616.29M USD | 329M USD | 233.66M USD | 2.79M USD | 6.69M USD |
| Cost of goods sold | 100.71M USD | 38.49M USD | 14.13M USD | 265K USD | 790K USD |
| Gross profit | 515.57M USD | 290.52M USD | 219.53M USD | 2.52M USD | 5.9M USD |
| Research and development | 160.22M USD | 94.29M USD | 76.19M USD | 125.35M USD | 222.58M USD |
| Selling, general, and administrative | 232.03M USD | 154.3M USD | 122.71M USD | 95.48M USD | 128.09M USD |
| Operating expenses | 392.25M USD | 248.59M USD | 198.9M USD | 220.84M USD | 350.67M USD |
| Interest expense | 26.73M USD | 24.03M USD | 12.62M USD | 10.19M USD | 5.64M USD |
| Depreciation and amortization | 244K USD | 280K USD | 423K USD | 515K USD | 494K USD |
| Operating income | 123.32M USD | 41.93M USD | 20.63M USD | −218.32M USD | −344.77M USD |
| Net income | 447.18M USD | 23.38M USD | 12.67M USD | −223.81M USD | −348.1M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$80.50
49.38% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 30, 2012 | 4:225 | — | — |
Stock split | Jul 14, 2011 | 1:50 | — | — |
Stock split | Sep 29, 2003 | 1:5 | — | — |
Effective Apr 30, 2012
4:225
Effective Jul 14, 2011
1:50
Effective Sep 29, 2003
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR395.07M0.35%107.63B USD0.06%$142.19+0.53%
Vanguard Morningstar Total Stock Market ETFVTI228.48M0.01%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM205.95M0.26%78.38B USD0.19%$288.89+0.41%
Vanguard Morningstar Small-Cap ETFVB164.84M0.09%183.4B USD0.03%$293.45+0.78%
State Street SPDR S&P Biotech ETFXBI121.36M1.15%10.57B USD0.35%$156.2-0.40%
Vanguard Morningstar Small-Cap Growth ETFVBK95.39M0.21%43.8B USD0.05%$340.69+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT87.79M3.07%2.85B USD0.55%$261.85-0.16%
Vanguard Extended Market ETFVXF79.01M0.08%93.7B USD0.05%$237.76+0.68%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKFirst Trust NYSE Arca Biotechnology Index FundFBTVanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
